Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies

Ka Yu Tse; Jihong Liu; Sung Jong Lee; David S.P. Tan

doi:10.3389/fonc.2022.882925

Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies

Ka Yu Tse
, Jihong Liu
, Sung Jong Lee
, David S.P. Tan

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Editorial

1 Scopus citations

Original language	English
Article number	882925
Journal	Frontiers in Oncology
Volume	12
DOIs	https://doi.org/10.3389/fonc.2022.882925
State	Published - 28 Mar 2022

Bibliographical note

Funding Information:
DSPT reports research support from Astra Zeneca, Karyopharm Therapeutics, Bayer, Roche, and has received personal fees and travel support from AstraZeneca, Novartis, Roche, Merck Serono, MSD, Bayer, Genmab, Takeda, Eisai, GSK and Clovis.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

DNA damage response
cervical cancer
gynecologic malignancies
homologous recombination repair deficiency
ovarian cancer

Access to Document

10.3389/fonc.2022.882925

Cite this

@article{92891c16a3354e1785af770348a6da5d,

title = "Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies",

keywords = "DNA damage response, cervical cancer, gynecologic malignancies, homologous recombination repair deficiency, ovarian cancer",

author = "Tse, \{Ka Yu\} and Jihong Liu and Lee, \{Sung Jong\} and Tan, \{David S.P.\}",

note = "Funding Information: DSPT reports research support from Astra Zeneca, Karyopharm Therapeutics, Bayer, Roche, and has received personal fees and travel support from AstraZeneca, Novartis, Roche, Merck Serono, MSD, Bayer, Genmab, Takeda, Eisai, GSK and Clovis. ",

year = "2022",

month = mar,

day = "28",

doi = "10.3389/fonc.2022.882925",

language = "English",

volume = "12",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Editorial

T2 - Harnessing DNA Damage Response in Gynecologic Malignancies

AU - Tse, Ka Yu

AU - Liu, Jihong

AU - Lee, Sung Jong

AU - Tan, David S.P.

N1 - Funding Information: DSPT reports research support from Astra Zeneca, Karyopharm Therapeutics, Bayer, Roche, and has received personal fees and travel support from AstraZeneca, Novartis, Roche, Merck Serono, MSD, Bayer, Genmab, Takeda, Eisai, GSK and Clovis.

PY - 2022/3/28

Y1 - 2022/3/28

KW - DNA damage response

KW - cervical cancer

KW - gynecologic malignancies

KW - homologous recombination repair deficiency

KW - ovarian cancer

UR - https://www.scopus.com/pages/publications/85128364311

U2 - 10.3389/fonc.2022.882925

DO - 10.3389/fonc.2022.882925

M3 - Editorial

AN - SCOPUS:85128364311

SN - 2234-943X

VL - 12

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 882925

ER -

Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Cite this